The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
Level 5 - mechanism / opinion, no new human data
Narrative review of gut physiology and pharmacological mechanisms with no systematic synthesis or original clinical data.
PubMed 17241888 · doi:10.1053/j.gastro.2006.11.002
What was done
This narrative review summarizes the physiology of the gastrointestinal serotonin signaling system—including enterochromaffin cell transducers, synthesis via tryptophan hydroxylases (TpH1 and TpH2), and inactivation by the serotonin reuptake transporter (SERT)—and outlines the therapeutic application of serotonin receptor agonists and antagonists in functional gastrointestinal disorders.
What was found
The abstract reports no quantitative experimental data or pooled effect sizes. It details pharmacological mechanisms, noting established uses for the 5-HT4 partial agonist tegaserod in constipation-predominant irritable bowel syndrome (IBS) and chronic constipation, 5-HT3 antagonists (alosetron, granisetron, ondansetron) for diarrhea-predominant IBS and chemotherapy-induced nausea, and potential roles for SSRIs, tricyclic antidepressants, and 5-HT1 agonists in functional bowel diseases and functional dyspepsia.
Why it matters
It establishes the biological framework connecting enteric serotonin synthesis, signaling, and transport to the rational design of targeted pharmacotherapies for disorders of gut motility and brain-gut interaction.
Limits
The abstract describes a non-systematic narrative review providing no primary numerical data, sample sizes, or formal risk-of-bias evaluation of the reviewed clinical trials.
Cited by
- context 95% of the body's serotonin is produced in the digestive tract.